By Randy Goodman, PhD In the evolving landscape of innovative therapeutics, radiopharmaceuticals stand out as a powerful modality to diagnose, target, and treat disease at the molecular level. This interest and excitement is re...
Radiopharmaceuticals
Navigating the CMC Journey in Radiopharmaceuticals
Insights from the “Tinker to Treasure” Webinar The development of radiopharmaceuticals offers tremendous potential for both the diagnosis and treatment of disease. However, turning early-stage research into a market-ready produ...
The Nonclinical Development Path for Radiopharmaceutical Drugs
By Dr. Bill F. Hodnick, DABT Microdose radiopharmaceutical drugs are a unique class of drugs characterized by single or infrequent administration of a very small dose (microdose) of a radiolabeled compound. These radiopharmaceu...
Facet is Proud to be a 2025 SNMMI Mars Shot Research Fund Donor
Facet Life Sciences contributed to and proudly supports the 2025 Mars Shot program, a Society of Nuclear Medicine and Molecular Imaging (SNMMI) initiative that provides funding to developers using nuclear medicine to find novel...
Facet Life Sciences Announces Partnership with Nucleus as Official Regulatory Partner
Facet Life Sciences specializes in guiding life science companies through the complex journey of drug, biologic, and medical device development and registration with the US FDA. Facet is pleased to announce the company’s role a...
gET sOCIAL